Risk factors associated with atherogenic dyslipidemia in the presence of optimal statin therapy

医学 血脂异常 他汀类 羟甲基戊二酰辅酶A还原酶抑制剂 低密度脂蛋白胆固醇 动脉粥样硬化性心血管疾病 内科学 重症监护医学 胆固醇 疾病
作者
Wang Zhao,Xi‐Long Zheng,Zenan Jiang,Xiaobo Liao,Shui‐Ping Zhao
出处
期刊:International Journal of Cardiology [Elsevier]
卷期号:248: 355-360 被引量:8
标识
DOI:10.1016/j.ijcard.2017.06.105
摘要

Background This study investigated the prevalence of atherogenic dyslipidemia (AD) in Chinese outpatients whose low-density lipoprotein cholesterol (LDL-C) levels reached the goals with statin monotherapy and evaluated the characteristics of these patients. Methods An analysis of the Dyslipidemia International Survey-China study that was carried out at 122 hospitals in China. Among patients reaching their LDL-C goals, the presence of AD was defined as triglyceride levels ≥1.7 mmol/L and/or low levels of high-density lipoprotein cholesterol (men: <1.0 mmol/L; women: <1.3 mmol/L). Results 22,039 patients receiving statin monotherapy were analyzed. According to the American National Cholesterol Education Program Adult Treatment Panel III, 13,088 patients reached LDL-C goals, and 7134 patients of them had AD. Age, male gender, BMI, sedentary lifestyle, diabetes mellitus, ischemic cerebrovascular disease, serum uric acid levels, and fasting plasma glucose (all P < 0.05) were independently associated with AD. Based on the Chinese guideline for the management of dyslipidemia, 13,551 patients reached LDL-C goals, and 7719 patients of them had AD. Age, male gender, BMI, sedentary lifestyle, coronary heart disease, serum uric acid levels, and fasting plasma glucose (all P < 0.05) were independently associated with AD. The intensity of statin therapy did not affect the prevalence of AD. Conclusion There was a high prevalence of AD in Chinese patients with optimal statin treatment. Some risk factors associated with AD were identified, but these factors were slightly different according to two criteria/guidelines. The intensity of statin therapy did not reduce the prevalence of AD. A combination lipid therapy may be more suitable for Chinese patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
深情安青应助啾啾采纳,获得10
1秒前
自然怀梦完成签到,获得积分10
5秒前
可爱的函函应助贰陆采纳,获得10
7秒前
8秒前
活泼雁兰发布了新的文献求助10
13秒前
彭于彦祖应助慈祥的翠桃采纳,获得30
14秒前
彭于彦祖应助慈祥的翠桃采纳,获得30
14秒前
彭于彦祖应助慈祥的翠桃采纳,获得10
14秒前
彭于彦祖应助慈祥的翠桃采纳,获得30
14秒前
carol应助慈祥的翠桃采纳,获得10
14秒前
monere应助慈祥的翠桃采纳,获得10
14秒前
14秒前
monere应助慈祥的翠桃采纳,获得10
14秒前
科研小白应助慈祥的翠桃采纳,获得10
14秒前
VDC应助慈祥的翠桃采纳,获得30
14秒前
19秒前
star完成签到,获得积分10
21秒前
英俊的铭应助没出门采纳,获得10
21秒前
22秒前
26秒前
28秒前
28秒前
彪悍的熊猫完成签到,获得积分10
32秒前
wanci应助wj采纳,获得10
33秒前
33秒前
zs完成签到 ,获得积分10
33秒前
王某人发布了新的文献求助10
34秒前
芝麻发布了新的文献求助10
35秒前
36秒前
38秒前
没出门发布了新的文献求助10
38秒前
40秒前
科研通AI2S应助负责的冷亦采纳,获得10
41秒前
41秒前
JamesPei应助suhua采纳,获得10
42秒前
龚喜發財完成签到,获得积分10
44秒前
优美鱼发布了新的文献求助10
44秒前
wj发布了新的文献求助10
45秒前
47秒前
tx发布了新的文献求助30
47秒前
高分求助中
The late Devonian Standard Conodont Zonation 2000
歯科矯正学 第7版(或第5版) 1004
Nickel superalloy market size, share, growth, trends, and forecast 2023-2030 1000
Semiconductor Process Reliability in Practice 1000
Smart but Scattered: The Revolutionary Executive Skills Approach to Helping Kids Reach Their Potential (第二版) 1000
Security Awareness: Applying Practical Cybersecurity in Your World 6th Edition 800
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 700
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3240868
求助须知:如何正确求助?哪些是违规求助? 2885568
关于积分的说明 8239149
捐赠科研通 2554008
什么是DOI,文献DOI怎么找? 1382120
科研通“疑难数据库(出版商)”最低求助积分说明 649471
邀请新用户注册赠送积分活动 625097